Proving that even the smallest drugmakers can sometimes find a buyer, Barrier Therapeutics
In a few short months, Barrier has gone from looking to pick up new compounds itself to entering the fold of privately held Stiefel. At $4.15 a share, the nearly 136% premium Stiefel is offering beyond Friday's closing price may seem like a great deal for Barrier shareholders, but remember that Barrier commanded more than $8 a share less than two years ago.
Both Stiefel and Barrier focus on marketing drugs to treat dermatological conditions. In the first quarter, Barrier had revenue of $8.4 million from its compounds, and it expected 2008 sales to top $40 million. This hasn't been enough to stanch the company's steady outflows of red ink, though; Barrier's operating cash flow declined more than $11 million in the most recent quarter.
With only $37 million in cash and equivalents on its balance sheet at the end of the quarter, Barrier thus had to either find a partner for its drugs, or submit to a potentially punishing new round of financing. This deal makes sense on Stiefel's end as well. Barrier's products will be worth more to a larger company that can better market such drugs, and put more resources into new clinical studies to improve their labels.
There has been a spate of activity in the dermatology-products space in recent weeks, most recently including Allergan's
Further Foolishness, no prescription required:
